Krebs Biochemicals & Industries Limited

CIN · L24110AP1991PLC103912

5th November, 2020

To,

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Scrip Code : 524518

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051

Name of Scrip : KREBSBIO

Dear Sir / Madam,

Sub : Outcome of Board Meeting

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ["SEBI LODR Regulations"], we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 5th November ,2020 :

(a) The Audited financial results for the quarter and Half Year ended 30th September, 2020 along with the Auditor's Limited Review Report thereon (Enclosed herewith) have been adopted by the Board.

Kindly note that the meeting was commenced at 12.00 PM and concluded at 03.30 PM

You are requested to take note of the above.

Thanking you,

Yours faithfully,
For Krebs Biochemicals & Industries Limited

Taruni Banda
Company Secretary

KREBS BIOCHEMICALS & INDUSTRIES LIMITED

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031

Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No: 8, Banjara Hills, Hyderabad - 500 034

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020

(Rs. In lacs)

Sl.No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2020 (Un Audited)	30.06.2020 (Un Audited)	30.09.2019 (Un Audited)	30.09.2020 (Un Audited)	30.09.2019 (Un Audited)	31.03.2020 (Audited)
	PART - 1						
1	Revenue from Operations						
	a) Net Sales / Income from Operations	1,139.17	768.00	508.18	1,907.18	810.11	2,358.38
	b) Other Operating Income	530.24	388.90	137.11	919.13	301.23	982.82
2	Other Income	7.14	5.02	6.51	12.16	24.32	36.52
3	**Total Income from operations (1+2)**	**1,676.55**	**1,161.92**	**651.80**	**2,838.47**	**1,135.66**	**3,377.73**
4	**Expenses**						
	a) Cost of Material Consumed	959.36	743.82	318.18	1,703.18	643.84	1,917.74
	b) Changes in Inventories of Finished goods, Work-In-Progress	(120.33)	(362.76)	107.06	(483.08)	24.51	(331.87)
	c) Employee Benefits Expenses	364.71	428.41	363.39	793.12	735.58	1,508.06
	d) Finance Costs	212.48	123.22	163.03	335.70	323.56	592.78
	e) Depreciation and Amortisation Expense	123.69	123.69	114.89	247.37	229.78	467.90
	f) Other Manufacturing Expenses	699.85	703.53	288.34	1,403.38	568.20	1,705.21
	g) Other Expenses	75.82	74.16	81.61	149.98	153.56	405.11
	Total Expenses (4)	**2,315.58**	**1,834.07**	**1,436.50**	**4,149.65**	**2,679.03**	**6,264.93**
5	**Profit / (Loss) before exceptional items and tax (3±4)**	**(639.03)**	**(672.15)**	**(784.70)**	**(1,311.18)**	**(1,543.37)**	**(2,887.20)**
6	**Exceptional Items:**						
	a) Depletion in Value of Inventory	-	-	-	-	-	-
	b) Amounts Written off/ written back	-	-	-	-	-	-
	c) Prior Period Income/(Expenditure)	-	-	-	-	-	-
	d) Profit on sale of Fixed Assets	-	-	-	-	-	-
7	**Profit / (Loss) before Tax (5 ± 6)**	**(639.03)**	**(672.15)**	**(784.70)**	**(1,311.18)**	**(1,543.37)**	**(2,887.20)**
8	**Tax Expense**						
	a) Current Tax	-	-	-	-	-	-
	b) Deferred Tax	-	-	-	-	-	-
9	**Profit / (Loss) for the period (7 ± 8)**	**(639.03)**	**(672.15)**	**(784.70)**	**(1,311.18)**	**(1,543.37)**	**(2,887.20)**
10	Other Comprehensive Income (OCI)						
i	Items that will not be reclassified to profit or Loss	-	-	-	-	-	(7.70)
ii	Income tax relating to items that will not be reclassified to profit or Loss	-	-	-	-	-	-
iii	Items that will be reclassified to profit or Loss	-	-	(35.47)	-	(69.03)	(119.39)
iv	Income tax relating to items that will be reclassified to profit or Loss	-	-	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)	**-**	**-**	**(35.47)**	**-**	**(69.03)**	**(127.08)**
11	**Total Comprehensive Income for the period(9 ± 10) (Comprising Profit (Loss) and other Comprehensive Income for the period)**	**(639.03)**	**(672.15)**	**(820.17)**	**(1,311.18)**	**(1,612.41)**	**(3,014.28)**
12	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	1962.06	1962.06	1663.06	1962.06	1,663.06	1800.06
13	Other Equity excluding Revaluation Reserve	-	-	-	-	-	(5,404.73)
14	**Earning Per Share (of Rs.10/- each) (not Annualised)**						
	a) Basic	(3.26)	(3.43)	(4.93)	(6.68)	(9.70)	(16.75)
	b) Diluted	(3.26)	(3.63)	(4.93)	(5.81)	(9.70)	(17.90)
15	Net Worth (including Retained Earnings)	-	-	-	-	-	(2,499.59)

See accompanying notes to the Financial results

1. The above unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on 05th November 2020. The results have been subjected to limited review by statutory auditors of the company.
2. The Company is operating in one segment only hence no segment results have been disclosed.
3. The company has considered the possible effects that may result from the pandemic relating to Covid 19 on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. In developing the assumptions relating to the future possible uncertainties in the global economic conditions, the Company has, at the date of approval of these standalone financial results, used internal and external sources of information, including economic forecasts and estimates from market sources, on the expected future performance of the company. On the basis of evaluation and current indicators of future economic conditions, the Company expects to recover the carrying amounts of these assets and does not anticipate any impairment to these financial and non -financial assets. However, the impact assessment of Covid-19 is a continuing process, given the uncertainties associated with its nature and duration. The company will continue to monitor any material changes to future economic conditions.
4. There is no significant effect on the manufacturing operations due to the pandemic related Covid-19. However delays in supply chain have had moderate effect in this quarter. We see things improving.
5. The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.

Avinash Ravi
Managing Director
DIN : 01616152

Krebs Biochemicals & Industries Ltd. Hyderabad

Place: Hyderabad
Date: 05.11.2020

KREBS BIOCHEMICALS & INDUSTRIES LIMITED
CIN:L24110AP1991PLC103912
Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031
Corp Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034

Statement of Assets and Liabilities as at 30th September,2020 **(Rs. In Lacs)**

Particulars	As at 30.09.2020 Un Audited	As at 31.03.2020 Audited
ASSETS		
Non Current Assets		
(a)Property, Plant and Equipment	10,102.20	10,336.56
(b)Capital Work in Progress	1,415.07	234.56
(c)Other Intangible Assets	179.25	192.27
(d)Intangible assets under development	184.71	184.71
(e)Financial Assets	157.21	153.65
(f)Other Non Current Assets	541.29	392.28
Total Non Current Assets	**12,579.74**	**11,494.03**
Current Assets		
(a) Inventories	1,945.26	1,499.56
(b) Financial Assets		
(i) Trade Receivables	134.76	20.21
(ii) Cash & Cash Equivalents	26.59	17.43
(iii) Other Financial Assets	2.10	8.17
(c)Other Current Assets	398.90	340.63
Total Current Assets	**2,507.61**	**1,885.99**
Total Assets	**15,087.35**	**13,380.02**
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	1,962.06	1,800.06
(b) Other Equity	(4,727.94)	(4,299.65)
Total Equity	**(2,765.88)**	**(2,499.59)**
Liabilities		
Non Current Liabilities		
(a)Financial Liabilities		
(i)Long Term Borrowings	8,191.40	6,550.58
(ii)Other Financial Liabilities	306.43	269.36
(b)Provisions	50.75	46.75
(c)Retirement benefit obligations	199.58	199.58
(d)Other Non Current Liabilities	4,500.00	4,500.00
Total Non Current Liabilities	**13,248.16**	**11,566.26**
Current Liabilities		
(a)Financial Liabilities		
(i)Borrowings		
(ii)Trade Payables		
(a) Total outstanding dues of micro and small enterprises	270.78	276.21
(b) Total outstanding dues of creditors other than micro and small enterprises	1,896.79	1,992.90
(iii)Other Financial Liabilities	1,981.04	977.43
(b)Other Current Liabilities	280.58	868.18
(c)Provisions	92.14	83.56
(d)Retirement benefit obligations	83.74	115.07
Total Current Liabilities	**4,605.06**	**4,313.35**
Total Equity and Liabilities	**15,087.35**	**13,380.02**

Krebs Biochemicals & Industries Ltd. Hyderabad

Avinash Ravi
Managing Director
DIN: 01616152

Place: Hyderabad
Date: 05-11-2020

KREBS BIOCHEMICALS & INDUSTRIES LIMITED
CIN:L24110AP1991PLC103912
Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031
Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No: 8, Banjara Hills, Hyderabad - 500 034

Additional disclosures as per Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sl No	Particulars	As at 30-09-2020		As at 31-03-2020	
1	i) Last due date for the payment of dividend of Non-convertible Redeemable preference shares (NCRPS)				
	a) 9% Non-Convertible Redeemable Preference Shares (Issued on 05-02-2020)	NA		NA	
	ii) Whether Dividend has been paid on due dates	NA		NA	
2	i) Last due date for the repayment of principal of NCRPS	NA		NA	
	ii) Whether principal has been repaid on due dates	NA		NA	
3	Next due date and amount for payment of dividend of NCRPS	(Rs.Lacs)	Date	(Rs.Lacs)	Date
	a) 9% Non-Convertible Redeemable Preference Shares (Issued on 05-02-2020)	NA	NA	NA	NA
4	Next due date and amount for the repayment of principal of NCRPS (falling due within next one year period)				
	a) 9% Non-Convertible Redeemable Preference Shares (Issued on 05-02-2020)	NA	NA	NA	NA
5	Next due date and amount for the repayment of principal of CPs (falling due within next one year period)	NA	NA	NA	NA
	Particulars	**As at 30-09-2020 (Rs.Lacs)**		**As at 31-03-2020 (Rs.Lacs)**	
6	Outstanding redeemable preference shares (quantity and value)				
	Quantity (in Lakhs)	30.00		30.00	
	Value	3,000.00		3,000.00	
7	Capital redemption reserve/debenture redemption reserve	-		-	
8	Net Worth*	(3,910.35)		(3,644.07)	
9	Net Profit/(Loss) after tax (Including Other comprehensive Income)	(1,311.18)		(3,014.29)	
10	Earning per share	(6.68)		(16.75)	
11	Debt-equity ratio [no.of times]**	(3.34)		(2.65)	
12	Debt Service Coverage ratio ***	(0.07)		(0.25)	
13	Interest Service coverage ratio ****	(2.91)		(3.87)	

Note:

1. * Net worth as per section 2(57) of Companies Act, 2013 (aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the audited balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation)
2. ** Debt-Equity Ratio = Total Borrowings divided by Equity
3. *** DSCR = EBITDA (Earnings before interest, Tax, depreciation and Amortization) divided by (Interest expenses & principal amount on Short & Long Tem barrowings)
4. **** ISCR = Profit before interest and exceptional items divided by interest expense
5. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the company at its meeting held on 5th November 2020.

Place: Hyderabad
Date: 05.11.2020

Krebs Biochemicals & Industries Ltd. Hyderabad

Avinash Ravi
Managing Director
DIN : 01616152

KREBS BIOCHEMICALS & INDUSTRIES LIMITED
CIN:L24110AP1991PLC103912
Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031
Corp Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034

Cash Flow Statement for the Half Year Ended September 30, 2020

(Rs. In Lacs)

Particulars	Half Year Ended 30.09.2020	Half Year Ended 30.09.2019
Cash Flow from Operating Activities		
Net Profit before tax and exceptional items	**(1,311.18)**	**(1,543.37)**
Adjustments for:		
Depreciation and Amortisation Expenses	247.37	229.78
Non Current provisions	4.00	-
Financial Charges	335.70	323.56
Operating Profit before Working Capital Changes	**(724.11)**	**(990.03)**
Changes in Working Capital		
(Increase)/Decrease in Inventories	(445.71)	(184.41)
(Increase)/Decrease in Trade Receivables	(114.56)	156.69
(Increase)/Decrease in Other Financial Assets	6.07	(11.40)
(Increase)/Decrease in Other Current Assets	(58.27)	(71.45)
(Increase)/Decrease in Financial Assets	(3.56)	(7.77)
(Increase)/Decrease in Other Non Current Assets	(149.01)	165.67
Increase /(Decrease) in Retirement benfit obligations	(31.33)	-
Increase/(Decrease) in Current Provisions	8.58	23.96
Increase/(Decrease) in Trade Payables	(101.55)	318.17
Increase/(Decrease) in Other Current financial laibilities	1,003.61	-
Increase/(Decrease) in Other Current Liabilities	(587.60)	(185.76)
Cash generated from Operations	**(473.31)**	**203.72**
Net Cash Flow from Operating Activities	**(1,197.42)**	**(786.31)**
Proceeds from / (Payment to) Capital Work-in-Progress	(1,180.51)	(645.79)
Proceeds from / (Payment to) Other Intangible Assets	-	-
Proceeds from / (Payment to) Other Financial Liabilities	37.07	63.19
Cash Flow from Investing Activities	**(1,143.44)**	**(582.60)**
Financial Charges	(335.70)	(323.56)
Proceeds from / (Payment to) long term borrowings	1,640.82	91.70
Proceeds from / (Payment to) Share Capital	1,044.90	-
Cash Flow from Financing Activities	**2,350.02**	**(231.86)**
Net Increase (Decrease) in Cash and Cash equivalents	9.16	(1,600.77)
Cash and Cash equivalents as at the beginning of the year	17.43	1,731.89
Cash and Cash equivalents at the end of the year	**26.59**	**131.12**

Krebs Biochemicals & Industries Ltd. Hyderabad

Avinash Ravi
Managing Director
DIN: 01616152

Place: Hyderabad
Date: 05.11.2020

BHAVANI & CO.,
CHARTERED ACCOUNTANTS
Tel : 040-2970 2640

Limited Review Report

Review Report to
The Board of Directors,
KREBS BIOCHEMICALS & INDUSTRIES LIMITED

a) We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. KREBS BIOCHEMICALS & INDUSTRIES LIMITED** ("the company") for the quarter ended **30th September, 2020** and the year to date from 1st July 2020 to 30th September 2020 (the "Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with SEBI circular No CIR/CFD/FAC/62/2016 dated 5th July 2016.

b) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.

c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other recognized accounting practices and policies has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bhavani &Co.
Chartered Accountants
Firm Registration No: 012139S

CA S Kavitha Padmini
Partner
Membership no: 229966
UDIN # 20229966AAAADH4575

Place : Hyderabad
Date : 05/11/2020

Plot No.48, Flat No.301, Micasa, Phase - I, Kavuri Hills, Hyderabad - 500 033.
E-mail : bhavaniandco@gmail.com